Clinical Trials Logo

Filter by:
NCT ID: NCT03376386 Completed - Clinical trials for Head and Neck Cancer

Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy

ADMIRE
Start date: December 21, 2017
Phase: N/A
Study type: Interventional

Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptive radiotherapy scheme. An FDG-PET/CT scan for re-delineation and re-planning will be made at the end of the second and fourth of week of radiotherapy. The non-responding part of the tumor on FDG-PET will receive a mild dose-escalation. Depending on the metabolic response, the entire tumor will receive 70 Gy or the residual FDG-avid area will receive 74 or 78 Gy.

NCT ID: NCT03376347 Completed - Clinical trials for Intraoperative Hypotension

Intraoperative Implementation of the Hypotension Probability Indicator

HYPE
Start date: November 8, 2017
Phase: N/A
Study type: Interventional

Reducing intraoperative hypotension using FlotracIQ with HPI software.

NCT ID: NCT03375801 Completed - Breast Cancer Clinical Trials

Implementing a Decision Aid for Breast Cancer and DCIS Patients Deciding on Their Radiation Treatment.

BRASA
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This is a pre-and post intervention study on the effect and implementation of an personalized decision aid for woman with breast cancer who face a decision on their radiation treatment.

NCT ID: NCT03375697 Completed - Alzheimer Disease Clinical Trials

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Start date: December 22, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of JNJ-63733657 following single ascending intravenous (IV) dose administration in healthy subjects (Part 1) and multiple ascending IV dose administrations in subjects with prodromal or mild Alzheimer's disease (AD) (Part 2).

NCT ID: NCT03374488 Completed - Clinical trials for UC (Urothelial Cancer)

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Start date: December 22, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.

NCT ID: NCT03374475 Completed - Clinical trials for Depressive Disorder, Major

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Start date: January 5, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 [HDRS17], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 [HAM-D6]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale [RRS], Sleep and Worry visual analogue scale [VAS], quantitative electro-encephalography [qEEG], heart rate variability [HRV] and others).

NCT ID: NCT03373461 Completed - IgA Nephropathy Clinical Trials

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

Efficacy and safety of LNP023 in IgAN patients

NCT ID: NCT03373253 Completed - Clinical trials for Depressive Disorder, Treatment-Resistant

Treatment-Resistant Depression Cohort in Europe

Start date: February 13, 2018
Phase:
Study type: Observational

The purpose of this study is to assess the participants socio-demographics and disease-related characteristics, long-term naturalistic treatment patterns and the clinical, social and economic outcomes of routine clinical practice in the treatment of participants with treatment-resistant depression (TRD) in a variety of European countries.

NCT ID: NCT03371810 Completed - Obesity Clinical Trials

Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder

PROUD
Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

Depression and obesity are very common among adolescents and young adults with attention-deficit/ hyperactivity disorder (ADHD). However, intervention programmes to prevent these comorbid disorders rarely exist. In a pilot randomized-controlled study we test two newly developed intervention programmes that do not involve medication: bright light therapy and physical exercise. Both interventions will be supported by a mobile Health application to monitor and feedback intervention success and booster patients' motivation.

NCT ID: NCT03370887 Completed - Heart Failure Clinical Trials

AZD8601 Study in CABG Patients

Start date: February 5, 2018
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacements are needed). The objective is to investigate safety and tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery with moderately impaired systolic function. At Visit 3 patients will receive either AZD8601 or placebo as epicardial injections and will then be followed up at 14 days (telephone visit) and 1, 3 and 6 months (on-site) post-surgery.